MoonLake Immunotherapeutics (NASDAQ: MLTX) announced that the FDA has granted Fast Track designation for sonelokimab for treating moderate-to-severe palmoplantar pustulosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE